Ekso Bionics (EKSO) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Individual investor ...

Several stocks posted notable moves in Wednesday's after-hours session, extending momentum from the regular trading day or reversing earlier trends. Earnings announcements and recent financing updates shaped activity across healthcare, biotech, and names, with PACS Group and Nutex Health standing out on fresh quarterly results. Below is a look at the companies making headlines after the close. PACS Group Inc. (PACS) surged in after-hours trading, climbing 45.48% to $24.48. The stock had already advanced 16 ...

Core Points - Ekso Bionics Holdings, Inc. has entered into a definitive agreement for the purchase and sale of 769,490 shares of common stock at a price of $4.81 per share, expected to close around October 30, 2025 [1] - The gross proceeds from this offering are anticipated to be $3.7 million, which will be used for general corporate purposes including research and development, administrative costs, and working capital needs [3] - The shares are being offered under a "shelf" registration statement previously filed with the SEC, and the offering will be conducted via a prospectus [4] Company Overview - Ekso Bionics is a leading developer of exoskeleton solutions aimed at enhancing human strength, endurance, and mobility for both medical and industrial applications [6] - The company focuses on improving health and quality of life through advanced robotics, and is recognized for its unique technologies that assist individuals with paralysis and enhance capabilities in various job sites [6] - Ekso Bionics is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol "EKSO" [6]

Financial Performance - Ekso Bionics reported a quarterly loss of $0.54 per share, better than the Zacks Consensus Estimate of a loss of $0.99, and an improvement from a loss of $1.5 per share a year ago, representing an earnings surprise of +45.45% [1] - The company posted revenues of $4.23 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 8.11%, compared to year-ago revenues of $4.13 million [2] - The current consensus EPS estimate for the upcoming quarter is -$0.54 on revenues of $5.65 million, and for the current fiscal year, it is -$1.17 on revenues of $15 million [7] Stock Performance - Ekso Bionics shares have declined approximately 46.2% since the beginning of the year, contrasting with the S&P 500's gain of 16.9% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] Industry Outlook - The Medical - Instruments industry, to which Ekso Bionics belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Market Performance and Sales - For the Personal Health market, the Ekso Indego Personal device received Medicare reimbursement approval at approximately $91,000, effective April 1, 2024, which is expected to increase demand among the estimated 309,000 individuals living with spinal cord injuries (SCI) in the U.S.[190] - The company anticipates that the majority of its revenue in 2025 will continue to come from Enterprise Health sales, while Personal Health product sales are expected to contribute more quarter over quarter as reimbursement processes are optimized[192] - The company has signed agreements with several partners, including National Seating & Mobility and Ottobock Patient Care, to enhance sales and reimbursement processes for the Ekso Indego Personal device, with expectations of increased claims submissions over the next 12 months[192] - The company is focused on expanding insurance coverage beyond Medicare and seeking additional indications of use for its products, which could significantly drive growth in Personal Health product sales[193] - The company’s revenue is highly dependent on market demand for exoskeleton products, influenced by factors such as awareness among rehabilitation clinics and reimbursement levels from Medicare and private insurers[196] Financial Performance - Revenue for the three months ended September 30, 2025, increased by $0.1 million, or 2%, to $4.227 million compared to $4.129 million in 2024, driven by higher sales volume of Enterprise Health devices in the Americas[212] - Gross profit for the same period increased by $0.3 million to $2.549 million, resulting in a gross margin of 60%, up from 53% in 2024, primarily due to lower device costs associated with multiple-device sales[213][214] - Total operating expenses decreased by $0.9 million, or 19%, to $3.951 million for the three months ended September 30, 2025, with significant reductions in sales and marketing (25%) and research and development (29%) expenses[216][217] - For the nine months ended September 30, 2025, revenue decreased by $3.2 million, or 25%, to $9.659 million, primarily due to lower sales volume in the EMEA region[223] - Gross profit for the nine months ended September 30, 2025, decreased by $1.6 million to $5.174 million, while gross margin slightly increased to 54% from 53% in 2024[224][225] Expenses and Losses - Sales and marketing expenses for the nine months ended September 30, 2025, decreased by $0.7 million, or 13%, attributed to lower headcount and payroll expenses[227] - The company reported a net loss of $1.421 million for the three months ended September 30, 2025, an improvement of $0.651 million, or 31%, compared to a net loss of $2.072 million in 2024[211] - Research and development expenses decreased by $0.6 million, or 21%, for the nine months ended September 30, 2025, compared to the same period in 2024[228] - General and administrative expenses increased by $0.3 million, or 5%, for the nine months ended September 30, 2025, compared to the same period in 2024[229] Cash Flow and Working Capital - As of September 30, 2025, working capital was $5.9 million, down from $11.3 million as of December 31, 2024[236] - Net cash used in operating activities decreased by $0.9 million, or 11%, for the nine months ended September 30, 2025, compared to the same period in 2024[242] - Net cash provided by financing activities was $3.7 million for the nine months ended September 30, 2025, primarily from the B. Riley Promissory Note and common stock sales[244] - The company expects operating cash requirements to continue exceeding cash provided by operations in the near term[247] - Management estimates that the company's cash will fund operations into the first quarter of 2026[247] Strategic Initiatives - The company is exploring strategic transactions, which may include acquisitions in different industries, and expects that any such transaction would require stockholder approval and involve the issuance of a substantial amount of company securities[195] - The company is actively developing its channel partner program to enhance reimbursement claims for the Ekso Indego Personal device, with successful claims being processed through appeals[192] Other Financial Metrics - Interest expense, net decreased by 77% for the three months ended September 30, 2025, primarily due to lower interest related to promissory notes[218] - Unrealized gain on foreign exchange for the three months ended September 30, 2025, was de minimis compared to a gain of $0.634 million in 2024[220] - The gain on revaluation of warrant liabilities was negligible for the three months ended September 30, 2025, reflecting the volatility in stock price and other factors[219] - Interest expense decreased by 27% for the nine months ended September 30, 2025, compared to the same period in 2024[230] - Unrealized gain on foreign exchange was $2.0 million for the nine months ended September 30, 2025, compared to $0.2 million for the same period in 2024[233] - Total contractual obligations as of September 30, 2025, amounted to $6.188 million, with $4.682 million due within one year[249]

Financial Performance - Revenue for Q3 2025 was $4.2 million, a 2% increase year-over-year and a 105% sequential increase from Q2 2025[3] - Gross profit for Q3 2025 was $2.5 million, with a gross margin of approximately 60.3%, up from 53.5% in Q3 2024[4] - Net loss for Q3 2025 improved by 31% year-over-year to $1.4 million, or $0.54 per share, compared to a net loss of $2.1 million, or $1.53 per share, in Q3 2024[7] Expenses - Sales and marketing expenses decreased to $1.3 million in Q3 2025 from $1.8 million in Q3 2024, primarily due to lower payroll expenses[5] - Research and development expenses for Q3 2025 were $0.6 million, down from $0.8 million in Q3 2024[6] Strategic Initiatives - The company launched eksoUniversity and delivered its first official CEU certification to a physical therapist in Connecticut[9] - The company is exploring strategic transactions, which may include acquisitions or the sale of its current business[10] Cash and Assets - As of September 30, 2025, the company had cash of $2.7 million, down from $4.5 million at the end of 2024[8] - Total current assets decreased to $14.8 million as of September 30, 2025, from $18.8 million at the end of 2024[15] - Total liabilities as of September 30, 2025, were $12.0 million, down from $13.9 million at the end of 2024[15]

Core Viewpoint - Ekso Bionics Holdings, Inc. reported a revenue rebound and improved financial metrics for Q3 2025, indicating successful navigation through previous challenges and a focus on growth strategy while managing resources [3][10]. Financial Performance - For Q3 2025, the company recorded revenue of $4.2 million, a 2% increase year-over-year from $4.1 million in Q3 2024, and a 105% sequential increase from $2.1 million in Q2 2025 [3][10]. - Gross profit for Q3 2025 was $2.5 million, with a gross margin of approximately 60.3%, up from $2.2 million and 53.5% in Q3 2024, driven by higher margin Enterprise Health sales and lower device costs [4][10]. - Net loss for Q3 2025 was $1.4 million, or $0.54 per share, representing a 31% improvement from a net loss of $2.1 million, or $1.53 per share, in Q3 2024 [7][10]. Expense Management - Sales and marketing expenses decreased to $1.3 million in Q3 2025 from $1.8 million in Q3 2024, primarily due to lower payroll expenses related to the Employee Retention Credit [5]. - Research and development expenses were reduced to $0.6 million in Q3 2025 from $0.8 million in Q3 2024, also due to lower payroll expenses and headcount [6]. - General and administrative expenses decreased to $2.1 million in Q3 2025 from $2.3 million in Q3 2024, attributed to lower payroll expenses, partially offset by higher legal costs [7]. Strategic Initiatives - The company is exploring strategic transactions, which may include acquiring a business in a different industry or selling its current business, with no assurances that any transaction will occur [9][11]. - The company launched eksoUniversity and delivered its first official CEU certification to a physical therapist in Connecticut [10]. Cash Position - As of September 30, 2025, the company had cash of $2.7 million, down from $4.5 million at the end of 2024 [8][15]. Balance Sheet Overview - Total assets as of September 30, 2025, were $21.7 million, a decrease from $26.7 million at the end of 2024 [15]. - Total liabilities were $12.0 million, down from $13.9 million at the end of 2024, while stockholders' equity decreased to $9.7 million from $12.7 million [15].

Improving health and quality of life with advanced robotics designed to enhance, amplify, and restore human function. Investor Presentation October 2025 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements. Forw ...

Core Viewpoint - Ekso Bionics (EKSO) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][2]. Earnings Estimates and Stock Price Movement - The Zacks rating system is effective for individual investors as it focuses on earnings estimate revisions, which are strongly correlated with near-term stock price movements [2][3]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [3]. Company Performance and Outlook - The upgrade for Ekso Bionics reflects an improvement in the company's underlying business, suggesting that investor sentiment may drive the stock price higher [4]. - Over the past three months, the Zacks Consensus Estimate for Ekso Bionics has increased by 77%, indicating a positive trend in earnings estimates [7]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [6]. - Ekso Bionics' upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [9].

Core Insights - Several small-cap stocks experienced significant gains in after-hours trading, driven by strategic updates, leadership changes, and pipeline developments, indicating renewed investor interest [1] Adaptimmune Therapeutics plc (ADAP) - ADAP's stock surged 30% in after-hours trading, reaching $0.2020 after a 98% gain during the regular session, closing at $0.16 [2] - The company reported a net loss of $30.3 million for Q2 2025, with total revenue of $13.7 million, primarily from product sales of TECELRA, which saw over 150% growth compared to Q1 [3] - In August, Adaptimmune sold several cell therapies to US WorldMeds for $55 million upfront, with potential future milestone payments of up to $30 million, allowing the company to repay its debt and restructure [4] Butterfly Network Inc. (BFLY) - BFLY's stock rose 10.58% in after-hours trading to $2.09, following a 15.95% increase during the regular session [4] - The company was recognized in TIME's list of the World's Top HealthTech Companies for 2025, and appointed a new Chief Technology Officer, enhancing its focus on innovation [5] - A recent study confirmed that Butterfly-enabled POCUS programs significantly reduce hospital stays and costs, validating its clinical impact [5] Aquestive Therapeutics Inc. (AQST) - AQST's stock increased 7.69% in after-hours trading to $5.32, continuing a year-to-date rise of nearly 39% [6] - The FDA confirmed it will not require an advisory committee meeting for AQST's NDA for Anaphylm, streamlining the regulatory process with a PDUFA date set for January 2026 [7] - The company secured a $75 million strategic funding agreement to support the potential launch of Anaphylm, reinforcing its commercial readiness [7] ALX Oncology Holdings Inc. (ALXO) - ALXO's stock rose 9.17% in after-hours trading to $1.19, following a 3.81% increase during the regular session [8] - Insider buying activity, particularly by CEO Jason Lettmann, who purchased 92,233 shares, has boosted investor confidence [9] - The company's lead candidate, Evorpacept, is in multiple Phase 1 and Phase 2 trials across various cancers, collaborating with major partners [9] Ekso Bionics Holdings Inc. (EKSO) - EKSO's stock increased 5.37% in after-hours trading to $4.51, following a 9.74% gain during the regular session [10] - The company's inclusion in the NVIDIA Connect Program has spotlighted its efforts to integrate AI into its technologies [11] - EKSO launched Virtual eksoUniversity to support continuing education for physical therapists, potentially broadening adoption of its rehabilitation devices [11] CEL-SCI Corp. (CVM) - CVM's stock rose 5.27% in after-hours trading to $9.39, after a 1.02% increase during the regular session [12] - The company completed a $10 million public offering to support ongoing clinical and regulatory efforts [13] - CEL-SCI filed for Breakthrough Medicine Designation in Saudi Arabia for its lead candidate, Multikine, which could expedite patient access and reimbursement [13]